NCT04271488

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

An Open-label Parallel-Group Study to Evaluate Pharmacokinetics of E7090 and Its Metabolite in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Eisai Co., Ltd. · Industry
• Sex: All
• Age: 20 Years – 79 Years
• Healthy volunteers: Accepted

Summary

The primary purpose of the study is to evaluate the effects of mild and moderate hepatic impairment on PK of tasurgratinib after a single dose administration.

Conditions

• Hepatic Impairment

Interventions

Type	Name	Description
DRUG	Tasurgratinib	Tasurgratinib oral tablet.
DRUG	Tasurgratinib	Tasurgratinib oral capsule.

Timeline

• Start date: 2020-02-27
• Primary completion: 2026-11-30
• Completion: 2026-11-30
• First posted: 2020-02-17
• Last updated: 2026-01-23

Locations

8 sites across 1 country: Japan